Abstract: Bifuran-modified polyester, polyethylene-terephthalate-co (2,2?-bifuran-5,5?-dicarboxylate), prepared by esterifying or transesterifying a diacid component comprising from 2 to 10 mole percent 2,2?-bifuran-5,5?-dicarboxylate and a diol component with a catalyst compound comprising metal present in an amount of from about 10 to about 450 ppm and polycondensation to form the polyester wherein the polyester has an inherent viscosity of at least 0.5 g/dL, a glass transition temperature (Tg) of 82° C. or more, a semicrystalline melting peak (Tm) with ?Hf equal to or greater than 5 J/g on the second heating ramp, and melting temperature (Tm) between 229° C. and 246° C. Reinforced compositions and shaped articles comprising bifuran-modified polyethylene terephthalate and methods of their production are also disclosed.

Abstract: Semicrystalline polyethylene-2,2?-bifuran-5,5?-dicarboxylate (PEBF) homopolyester or copolyester with up to 5 mole percent isophthalate or up to 2.7 mole percent terephthalate, based on the diacid component, or up to 2.5 mole percent 1,4-cyclohexanedimethanol (CHDM), based on the diol component, prepared by esterifying or transesterifying the diacid and the diol components with a catalyst including about 10 to about 50 ppm wt metal, and polycondensation, wherein the bifuran polyester has an intrinsic viscosity of at least 0.4 g/dL and a semicrystalline melting peak (Tm) with ?Hf equal to or greater than 5 J/g on the second heating ramp.

Abstract: Copolyesters such as polyethylene terephthalate (PET) or polyethylene furanoate (PEF) modified with bifuran polyacids such as dimethyl-2,2?-bifuran-5,5?-dicarboxylate (BFE), 2,2?-bifuran-5,5?-dicarboxylic acid (BDA), or bis(2-hydroxyethyl)-2,2?-bifuran-5,5?-dicarboxylate (BHEB), and/or bifuran polyhydroxyls, may have improved properties such as glass transition temperature (Tg), tensile modulus, barrier properties, crystallinity, and/or impact strength. Polyethylene terephthalate-co-bifuranoate (PETBF) has an improved Tg. Also described are polyethylene furanoate-co-bifuranoates (PEFBF).

Abstract: Semicrystalline bifuran polyesters wherein the diacid and/or diol components include bifuran units such as those derived from 2,2?-bifuran-5,5?-dicarboxylic acid (BFA), dimethyl-2,2?-bifuran-5,5?-dicarboxylate (BFE), and/or bis(hydroxyethyl) bifuranoate (BHEB) Polyethylene-BFE (PEBF) having a high ?Hf and high Tg determined by DSC on the second heating ramp is described. Polybutylene-BFE (PBBF), polyhexylene-BFE (PHBF), polypropylene-BFE (PPBF), etc., are also described. Method for making bifuran polyesters includes melt esterification or transesterification and polycondensation of one or more monomers comprising a diacid component and a diol component, wherein the one or more monomers include a bifuran monomer, such as BFA, BFE, BHEB or BFD. Also described is a method of forming a bifuran polyester prepolymer in the melt, pelletization, crystallization, and solid state polymerization.

Abstract: The present invention is directed to substituted propylamine derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

Abstract: The present invention is directed to phenylaminopropanol derivatives of formulae I, II, and III: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, schizophrenia, and combinations thereof.

Abstract: This invention provides estrogen receptor modulators having the structure where R1—R5 are defined in the specification; or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein, R1, R2, R3, R4, R5, and R6 are as defined in the specification, or a N-oxide thereof or a pharmaceutically acceptable salt thereof or a prodrug thereof.

Abstract: The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

Abstract: The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

Abstract: A financial scenario modeling and analysis tool, including a graphical user interface which enables a user of the tool to create a graphical model of a financial scenario, generally including at least one financial transaction, on a display screen, and an engine operable, in response to creation of the graphical model, to automatically generate information, such as financial or mathematical information, which at least partially models at least a part of the financial scenario using information collected by the engine during creation of the graphical model. The graphical user interface enables the user to create party graphics respectively representing parties to the financial deal, and to generate financial instrument graphics representing financial instruments, wherein each financial instrument graphic connects two of the party graphics.

Abstract: The present invention is directed to substituted aryl cycloalkanoyl derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein, R1, R2, R3, R4, R5, and R6 are as defined in the specification, or a N-oxide thereof or a pharmaceutically acceptable salt thereof or a prodrug thereof.

Abstract: This invention provides estrogen receptor modulators having the structure where R1-R5 are as defined in the specification; or a pharmaceutically acceptable salt thereof.